After losing the battle for Allergan's control, Valeant Pharmaceuticals has...

After losing the battle for Allergan's control, Valeant Pharmaceuticals has announced a definitive agreement to acquire Salix Pharmaceuticals, which specializes in gastrointestinal drugs, for an enterprise value of about $14.5 billion

You need to register to continue reading this article

Already subscribe to Eyewear intelligence? Sign in here

Register to continue reading

By registering today you will have access to:

  • 3 industry news articles per month

For full access and to receive in-depth news, analysis and more, become a member today

For more content and resources become a member? View our membership packages.